A Randomized, Double-blind, Parallel Group, 14-day, Multi-Center Study to Evaluate the Safety of PT003, PT005, PT001 and Foradil Aerolizer (12 microg, Open Label) as Evaluated by Holter Monitoring, in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD).

Trial Profile

A Randomized, Double-blind, Parallel Group, 14-day, Multi-Center Study to Evaluate the Safety of PT003, PT005, PT001 and Foradil Aerolizer (12 microg, Open Label) as Evaluated by Holter Monitoring, in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD).

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Feb 2017

At a glance

  • Drugs Formoterol/glycopyrrolate (Primary) ; Glycopyrrolate (Primary) ; Formoterol
  • Indications Chronic obstructive pulmonary disease
  • Focus Adverse reactions
  • Sponsors Pearl Therapeutics
  • Most Recent Events

    • 11 Sep 2013 Pooled tolerability results presented at the 23rd Annual Congress of the European Respiratory Society.
    • 22 May 2013 Tolerability results presented at the 109th International Conference of the American Thoracic Society.
    • 06 Jan 2012 Status changed from recruiting to completed, according to a Pearl Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top